Phase 1 oncology trials are undergoing a major shift. Traditional 3+3 designs no longer meet regulatory expectations for dose optimization or the complexity of next-generation therapies. Sponsors now need richer early dose-finding data, broader dose exploration, and stronger justification for recommended Phase 2 doses.
